TSS
PMCB icon

Two Sigma Securities’s PharmaCyte Biotech PMCB Stock Holding History

Two Sigma Securities’s Portfolio PMCB Stock Details PMCB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$10.9K Sell
16,360
-8,193
-33% -$6.27K ﹤0.01% 1458
2025
Q4 		$17.8K Buy
+24,553
New +$22.1K ﹤0.01% 1198
2024
Q3 		– Sell
-27,750
Closed -$54.4K – 3464
2024
Q2 		$54.4K Buy
+27,750
New +$59.8K ﹤0.01% 2565

Other funds holding PMCB

Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
XT
XTX Topco George Town, Cayman Islands $5.75B AUM 30.56% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
VF
Virtu Financial New York $2.41B AUM 48.35% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
SSA
Schonfeld Strategic Advisors New York $14.2B AUM 37.17% 1-Year Est. Return
HF
HRT Financial New York $40.1B AUM 58.22% 1-Year Est. Return
VFT
Vanguard Fiduciary Trust Malvern, Pennsylvania $396B AUM

Two Sigma Securities's PMCB Position: Q1 2026 in Review

Two Sigma Securities reduced its PharmaCyte Biotech (PMCB) stake by 33% in Q1 2026, selling an estimated $6.27K and leaving 16,360 shares worth $10.9K. The position accounts for ﹤0.01% of the portfolio, ranked #1458.

Two Sigma Securities first reported a position in PMCB in Q2 2024 and has held it in 3 quarters since. The position peaked at $54.4K in Q2 2024. 32 funds tracked by Wall St. Rank hold PMCB as of Q1 2026.

  • Two Sigma Securities held 16,360 shares of PharmaCyte Biotech worth $10.9K as of Q1 2026.
  • Two Sigma Securities sold 8,193 PharmaCyte Biotech shares in Q1 2026, an estimated $6.27K.
  • PharmaCyte Biotech made up ﹤0.01% of Two Sigma Securities's portfolio in Q1 2026, its #1458 holding.
  • Two Sigma Securities first reported a position in PharmaCyte Biotech in Q2 2024 and has held it in 3 quarters since.
  • Two Sigma Securities's PharmaCyte Biotech position peaked at $54.4K in Q2 2024.
  • 32 funds tracked by Wall St. Rank held PharmaCyte Biotech as of Q1 2026.

Based on Two Sigma Securities's 13F filing for Q1 2026, filed 15 May 2026.